SINOPHARM

Sinopharm Group fell 1.53% to HK$17.38 today, extending its recent downtrend as investors remain cautious on earnings growth. The stock opened near HK$17.60 but retreated through the afternoon session to close, with total turnover of approximately HK$1.03 billion. Year-to-date, the stock has declined 11.91%, down 22.2% from its February 52-week high of HK$22.34, though up 13.74% from its June low of HK$15.28. Recent quarterly results reveal decelerating growth with Q1 EPS up just 1.36% year-over-year and net profit up 2.73%, a significant deceleration from Q4's growth of 8.36% and 9.09% respectively, while operating revenue growth held steady at 5.19% YoY. The stock trades at exceptionally low valuations with PE of 6.73x and PB of 0.56x, offering a dividend yield of 4.55%. Analyst sentiment is mixed—Goldman Sachs and Daiwa have cut target prices to HK$19.07 and HK$18 respectively, while CICC and CLSA maintain buy ratings. Recent catalysts include a strategic partnership with Pfizer and a shareholder mandate for up to 10% H-Share buyback, though the market awaits evidence of stabilizing earnings momentum.

Sinopharm Group closed at HK$17.65, down 0.28% from yesterday's HK$17.70, with intraday range between HK$17.50 and HK$17.77. The muted trading reflects underlying earnings slowdown: Q1 2026 revenue of HK$159.59B grew only 5.19% year-over-year, while EPS of HK$0.5102 increased just 1.36%, significantly below prior quarters' pace. As a pharmaceutical wholesaler, the company's net margin remains razor-thin at just over 1%, limiting profit growth drivers. Recent strategic partnership with Pfizer and dividend confirmation provide some support, but market enthusiasm remains subdued. Valuation appears attractive: the stock trades at PE 6.84 and PB 0.57, down 21% from its 52-week high of HK$22.34 but up 15.51% from the June low of HK$15.28. Daiwa downgraded to Hold with a HK$18 target price in late June, with current price near the target. However, the turnover rate of just 0.29% signals severe lack of buying interest, limiting how much the valuation discount can translate into positive momentum.

Sinopharm rose marginally by 0.47% to HKD17.25 today, with modest turnover (0.26%) and muted trading interest. The stock briefly surged to HKD17.32 in morning session but retreated; afternoon trading saw a small bounce from a lower open at HKD17.17. From a valuation perspective, the stock has declined 12.57% year-to-date from HKD19.73 and trades 22.78% below its 52-week high of HKD22.34 set on February 24, though it sits 12.89% above its recent 52-week low. Q1 2026 results showed revenue growth of 5.19% to HKD159.6 billion, but net profit growth slowed to 2.73% year-over-year, with a slim 1.0% margin. The valuation appears deeply discounted at PE 6.68x and PB 0.56x, with a 4.58% dividend yield offering defensive appeal. Recent developments including a strategic partnership with Pfizer and Daiwa's target price of HKD18 provide some support, though sparse trading volume suggests limited market conviction, and the deceleration in profit growth warrants monitoring.

Sinopharm rose 2% to HKD 17.17 today, boosted by Citi's recent buy rating. The morning session opened at HKD 16.88, while the afternoon rallied from HKD 17.05 to an intraday high of HKD 17.20. Q1 revenue reached RMB 159.6 billion, up 5.19% YoY, but EPS of HKD 0.51 grew only 1.36% and slowed from Q4; net profit growth decelerated from Q4's 9.09% to 2.73%, though the company maintained its 2025 dividend payout of RMB 0.69 per share. At just 6.65x P/E and 0.55x P/B, the stock is down 12.98% year-to-date and off 23% from its 52-week high of HKD 22.34. Daiwa maintains a Hold rating with an HKD 18 target price, diverging from Citi's Buy and reflecting market disagreement on growth recovery.

Sinopharm closed at HK$16.84, down 0.5% from the prior close of HK$16.93, as capital rotates within Hong Kong equities away from traditional defensive healthcare toward AI infrastructure and growth sectors. Sentiment among analysts remains divided: while Citi recently issued a Buy rating, prior targets from Daiwa (HK$18) and Goldman Sachs (HK$19.07) sit above the current price, underscoring skepticism around growth durability. Q1 results added downside pressure, with revenue growth of 5.19% year-over-year decelerating from Q4's 5.71%, while net profit expanded just 2.73% year-over-year, a notable slowdown from Q4's 9.09%. The stock has lost 14.65% year-to-date and trades 24.62% below its 52-week high of HK$22.34, although a depressed P/E of 6.52 and dividend yield of 4.69% provide valuation ballast.